Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex
This article was originally published in The Pink Sheet Daily
Executive Summary
Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.
You may also be interested in...
TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s Disease His Way: An Interview With PharmAsia News (Part 2 of 2)
Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).
TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s His Way: An Interview With PharmAsia News (Part 1 of 2)
Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).
Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.